Arcutis Biotherapeutics

Edit info

Founded: 2019

Location: Westlake Village, CA

Employee range: 50 - 200

Clinical stage: COM

Therapy area: Plaque psoriasis

Drug types: DRM, IMM

Lead product: Zoryve (romflumilast cream)

Funding: $150M stock Aug 2022; $183M IPO Jan 2020; $94.5M C Oct 2019

Investors: Frazier Healthcare Partners

arcutis.com

linkedin.com

job board

Drug notes:

Also Clin3 atopic dermatitis; Romflumilast foam Clin3 seborrheic dermatitis, Clin3 psoriasis; ARQ-255 Clin1 alopecia areata; ARQ-252 Clin0 hand eczema, Clin0 vitiligo; ARQ-234 Clin0 atopic dermatitis

About:

Arcutis Biotherapeutics is developing small molecule therapeutics for the treatment of immune-mediated dermatological diseases. Skin diseases like dermatitis, psoriasis and eczema are united by their immune-mediated pathology. Arcutis is using their deep medical dermatology expertise and a unique drug development platform to create topical product therapies for patients with these conditions. With this platform, Arcutis is building a robust pipeline that includes molecules developed from key targets of inflammatory dermatological conditions such as PDE4 and JAK1. These formulations have achieved significant results in their clinical trials for Atopic Dermatitis with multiple other clinical programs in development.